文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.

作者信息

Chen Chen, Liu Sasa, Ma Yanfen

机构信息

Department of Cardiology, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, 710061, China.

Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, 710061, China.

出版信息

Heliyon. 2024 Nov 12;10(22):e40329. doi: 10.1016/j.heliyon.2024.e40329. eCollection 2024 Nov 30.


DOI:10.1016/j.heliyon.2024.e40329
PMID:39624281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609644/
Abstract

BACKGROUND: CD73 is adenosine generation molecule, which is involved in the immune regulation. However, the roles of CD73 in the tumor microenvironment remain unknown. METHODS: CD73 expression levels in pan-cancers were analyzed, based on The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Human Protein ALTAS (HPA) databases. Kaplan-Meier (KM) plotter was used to analyze the prognostic values of CD73. Immune scores in pan-cancers was evaluated by ESTIMATE. TIMER2.0 and UCSCXena were used to explore the correlation between CD73 and immune infiltration/immune checkpoints/tumor mutation burden (TMB)/microsatellite instability (MSI). CD73 expression correlated genes in tumor tissues were screened by using LinkedOmics tool. RESULTS: Firstly, CD73 was significant increased in following cancer types: esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD) and stomach adenocarcinoma (STAD). Secondly, high CD73 expression was associated with poor overall survival in patients with breast invasive carcinoma (BRCA), CESC, HNSC, liver hepatocellular carcinoma (LIHC), LUAD, lung squamous cell carcinoma (LUSC), PAAD and STAD. However, in KIRC and UCEC, patients high CD73 expression showed a favorable prognosis. Thirdly, the immune scores of the high CD73 expression in bladder urothelial carcinoma (BLCA), BRCA, kidney chromophobe (KICH), LUAD, LUSC, ovarian serous cystadenocarcinoma (OV), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), and skin cutaneous melanoma (SKCM) were significant higher than that of patients with low CD73 expression. Furthermore, we observed a positive correlation between CD73 and the multiple immune cells infiltration, including CD4 memory T cells, CD8 T cells, Treg cells, myeloid DC and macrophage, particularly in BRCA and LUAD. There was no strong correlation between CD73 and TMB/MSI. In LUAD, CD73 expression correlated genes were mainly enrichment in positive regulation of cell proliferation, cell adhesion, positive regulation of kinase activity, cellular response to LPS. However, in UCEC, CD73 correlated genes were mainly associated with fatty acid omega-oxidation, protein localization to endoplasmic reticulum exit site, endoplasmic reticulum to Golgi vesicle-mediated transport. CONCLUSION: CD73 could be used to predict the prognosis of patients with several cancers. The potential functional mechanism of CD73 involved in cancer progress may not only dependent on its immunomodulatory effects.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/07f54b15b302/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/d38b41a50662/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/d750c8532167/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/ed879e52049d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/f89f5ef5bdb9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/07f54b15b302/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/d38b41a50662/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/d750c8532167/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/ed879e52049d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/f89f5ef5bdb9/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5599/11609644/07f54b15b302/gr5.jpg

相似文献

[1]
Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.

Heliyon. 2024-11-12

[2]
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.

Comput Struct Biotechnol J. 2022-6-18

[3]
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.

Front Immunol. 2021

[4]
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.

Neurol Res. 2024-3

[5]
Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Front Immunol. 2022

[6]
Identifies microtubule-binding protein as a novel cancer biomarker associated with ferroptosis and tumor microenvironment.

Comput Struct Biotechnol J. 2022-6-24

[7]
Comprehensive analysis of the novel omicron receptor AXL in cancers.

Comput Struct Biotechnol J. 2022

[8]
Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.

Comput Struct Biotechnol J. 2022-9-17

[9]
The molecular feature of macrophages in tumor immune microenvironment of glioma patients.

Comput Struct Biotechnol J. 2021-8-14

[10]
PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.

Comput Struct Biotechnol J. 2020-3-19

本文引用的文献

[1]
Investigation of co-treatment multi-targeting approaches in breast cancer cell lines.

Eur J Pharmacol. 2024-3-5

[2]
Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.

Int J Biol Sci. 2024

[3]
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.

Int J Mol Sci. 2023-10-5

[4]
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.

Support Care Cancer. 2023-10-11

[5]
Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer.

Front Oncol. 2023-7-13

[6]
Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells.

Cell Death Discov. 2023-6-30

[7]
Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner.

Nat Commun. 2023-6-8

[8]
Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Cancer Res Treat. 2023-10

[9]
Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery.

J Cancer Res Clin Oncol. 2023-8

[10]
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.

Cancer Immunol Immunother. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索